Video

Dr. Taneja Discusses Multiparametric MRI in Prostate Cancer

Samir Taneja, MD, James M. Neissa and Janet Riha Neissa professor of urologic oncology, vice chair, Department of Urology, professor, Department of Radiology, co-director, Smilow Comprehensive Prostate Cancer Center, director, Urologic Oncology, Genito-Urologic program leader, NYU Langone’s Perlmutter Cancer Center, discusses multiparametric MRI in prostate cancer.

Samir Taneja, MD, James M. Neissa and Janet Riha Neissa professor of urologic oncology, vice chair, Department of Urology, professor, Department of Radiology, co-director, Smilow Comprehensive Prostate Cancer Center, director, Urologic Oncology, Genito-Urologic program leader, NYU Langone’s Perlmutter Cancer Center, discusses multiparametric MRI in prostate cancer.

The advent of multiparametric MRI has allowed radiation oncologists to use different functional sequences to better assess the prostate and determine the severity of the cancer. In an additional effort to better image the prostate, Taneja says that pre-biopsy MRI is an innovative technique used at NYU Langone. This technique provides the opportunity to better monitor the disease than with fewer biopsies.

More precise imaging techniques allow physicians to better diagnose, risk-assess, localize, and choose treatments for prostate cancer more accurately. Prior data published in the Journal of Urology showed that MRI-guided biopsies were 3 times as likely to identify cancer compared with traditional biopsies. This has resulted in a reduction of side effects for many patients whose cancer is lower-risk, as imaging can spare them from conventional therapy.

Related Videos
Jennifer Scalici, MD
Steven H. Lin, MD, PhD
Anna Weiss, MD, associate professor, Department of Surgery, Oncology, associate professor, Cancer Center, University of Rochester Medicine
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Hematology/Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Victor Moreno, MD, PhD
Tiago Biachi, MD, PhD
Dr Girard on De Novo and Acquired Resistance Alterations in HER2-Altered NSCLC
Elias Jabbour, MD
Daniel DeAngelo, MD, PhD
Douglas W. Sborov, MD, MS